Clinical Trials and Research

Cardiac transthyretin amyloidosis (ATTR-CA) is caused by myocardial deposition of misfolded transthyretin, leading to progressive heart failure. Disease pathology,…

Cardiac amyloidosis (CA) frequently coexists with atrial fibrillation (AF), but the extent and impact of this relationship remain unclear. This study investigates…

AbstractTransthyretin (TTR) amyloid cardiomyopathy occurs when stable TTR, normally a 4-protein tetramer, becomes misfolded and aggregates to form amyloid fibrils…

Key TakeawaysTransthyretin amyloid cardiomyopathy is increasingly diagnosed in the US (~120,000 affected), particularly among older adults and men, and remains…

Impact of disease-modifying therapies on imaging parameters in cardiac amyloidosis: A systematic review and meta-analysis.

LOS ANGELES - Immix Biopharma, Inc. (NASDAQ:IMMX) announced today the completion of enrollment in its NEXICART-2 trial, a Phase 2 study evaluating CAR-T therapy NXC…

Open-Label Extension of the ATTRibute-CM Randomized Clinical TrialKey PointsQuestion  Is long-term treatment with acoramidis in transthyretin amyloid…

LOS ANGELES, CA, March 30, 2026 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), the global leader in relapsed/refractory…

Analyses presented at ACC reinforce the totality of data for vutrisiran in patients with ATTR-CM including the impact on cardiovascular outcomes across a range of…

AbstractCrescentic renal amyloidosis is a rare complication of light-chain (AL) amyloidosis. We report the case of a 73-year-old man with AL amyloidosis involving…